A naturally occurring copper-binding tripeptide studied for skin remodeling, collagen support, and tissue repair signaling.
Pre-loaded with a typical GHK-Cu vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for GHK-Cu. Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 500 mcg – 2 mg | daily | subcutaneous | Commonly cited in research and compounding reference protocols for subcutaneous investigation Often framed as roughly 0.5-2 mg/day in secondary protocol summaries; robust injectable human PK trials are limited. |
| Not a fixed mcg value | 1-2 times daily | topical | Topical dermatology and cosmetic research formulations Literature more often reports cream/serum concentrations around 0.1-2% rather than absolute mcg doses. |
People searching this page also look for: ghk-cu peptide injection dosage, ghk-cu peptide injection dosage chart, ghk-cu peptide injection dosage per day, ghk-cu peptide dosage chart, ghk-cu peptide injection dosage chart pdf, ghk-cu peptide dosage per day, ghk-cu peptide injection dosage 50mg, ghk cu peptide dosage.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. It appears in human plasma, saliva, and urine, and circulating levels are reported to decline with age. In research settings it is treated as a small signaling peptide that can shuttle copper into cells and influence gene programs tied to extracellular matrix turnover.
Investigators study GHK-Cu because multiple cell-culture and animal models link it to organized collagen and glycosaminoglycan synthesis, balanced matrix metalloproteinase activity, and support for angiogenesis during tissue remodeling. Reviews by Pickart and colleagues summarize effects across skin regeneration, wound models, and broader protective gene-expression patterns. Most human data involve topical cosmetic or dermatology formulations rather than large injectable trials.
For laboratory and research-use-only contexts, GHK-Cu is typically supplied as a lyophilized powder for reconstitution. Published work frames it as a reference compound for studying copper-dependent repair pathways, not as an approved systemic therapy for disease. Any dosage figures discussed on educational pages are literature-reported ranges for reference, not recommendations.
GHK binds Cu2+ with high affinity and can deliver bioavailable copper while acting as a signaling ligand. Reported cellular effects include modulation of TGF-beta and integrin-related pathways, upregulation of collagen, elastin, and proteoglycan synthesis, and coordinated control of MMPs and their inhibitors so matrix breakdown and rebuild stay balanced. Antioxidant and anti-inflammatory actions are also described, including support for superoxide dismutase activity and reductions in selected pro-inflammatory cytokines in experimental systems. Together these actions position GHK-Cu as a remodeler of the extracellular matrix rather than a simple structural filler.
skin remodeling · wound healing · extracellular matrix biology · collagen synthesis · anti-inflammatory signaling
Dermatology and wound-healing researchers use GHK-Cu to probe copper-dependent matrix remodeling and fibroblast behavior. Cosmetic scientists evaluate topical formulations for photoaging and barrier metrics. Regenerative-biology labs study its gene-expression footprint in repair models. Interest is strongest among groups working on tissue architecture, not general endocrinology.
Keep lyophilized vials refrigerated or frozen per supplier COA, protected from light and moisture. After reconstitution with bacteriostatic water, refrigerate and use within the stability window stated by the supplier, commonly cited as up to 30 days when kept cold and uncontaminated.
In research catalogs GHK-Cu often appears alongside BPC-157 and TB-500/thymosin beta-4 in multi-peptide repair blends (for example Glow or Klow) because the components target complementary matrix, angiogenic, and inflammatory pathways. It is also studied next to topical retinoids or growth-factor serums in dermatology work. Stacking discussions should stay per-component: each peptide has its own concentration math.
The questions people actually search for, answered plainly.
There is no single universal clinical dose for research-grade GHK-Cu injectables. Secondary research-protocol summaries commonly cite roughly 500-2,000 mcg (0.5-2 mg) subcutaneously per day, while topical work uses percent-strength creams rather than mcg injections. Treat published figures as reference ranges from literature and lab practice, not personal medical advice. Use a reconstitution calculator to convert vial milligrams and diluent volume into mcg per unit.
Common research vial sizes are 50 mg or 100 mg. Adding 3 mL or 5 mL of bacteriostatic water are frequent choices because they yield easy insulin-syringe math. Example: 50 mg in 5 mL gives 10 mg/mL, so 0.1 mL (10 units on a U-100 syringe) equals 1,000 mcg. Always confirm your vial label and calculate from actual mg and mL.
Daily subcutaneous amounts most often discussed in research-protocol writeups fall near 1 mg/day, with a broader cited band of about 0.5-2 mg. Frequency is usually once daily in those summaries. Human injectable dose-finding literature is thinner than the topical evidence base, so ranges should be read as commonly reported reference values.
A practical chart maps reconstituted concentration to syringe units. If a 50 mg vial is mixed with 5 mL bac water (10 mg/mL), then 5 units = 500 mcg, 10 units = 1,000 mcg, and 20 units = 2,000 mcg on a U-100 insulin syringe. Build the chart from your exact vial size and diluent volume rather than copying a generic image.
Topical dermatology studies often run 8-12 weeks when measuring wrinkle, density, or elasticity endpoints. Preclinical wound models can show earlier histologic changes. Timeline depends on model, route, concentration, and outcome measure. Educational pages should not promise personal results.
The free tripeptide is generally described as short-acting in systemic circulation, with secondary sources often placing clearance on the order of under an hour. Copper binding, tissue uptake, and topical vehicles change effective duration at the application site. Primary PK packages for every research route are not uniform.
Research blends frequently pair GHK-Cu with BPC-157 and TB-500, and sometimes KPV, to cover matrix remodeling plus cytoprotection and actin-related cell migration. Combination products still require per-component dose accounting. Compatibility in a multi-peptide vial does not equal clinical endorsement of a stack.
Dose (mcg) = concentration (mg/mL) x volume drawn (mL) x 1,000. Concentration = vial_mg / diluent_mL. Example: 100 mg / 5 mL = 20 mg/mL; drawing 0.05 mL delivers 1 mg (1,000 mcg). Point researchers to an on-site peptide dosage calculator to avoid unit errors.
Primary literature on GHK-Cu. Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides